Beruflich Dokumente
Kultur Dokumente
Contents
[hide]
1 Introduction
2 Genome Structure
3 Cell Structure
4 Metabolism
5 Epidemiology
6 Pathology
7 Multidrug-Resistance
9 Future Work
10 References
Introduction
Figure 2. SEM depiction of a cluster of gram-negative, non-motile, rod bacteria Acinetobacter baumannii.
A. baumannii (Figure 1) is a pathogenic species of bacteria whose spread has recently gained
worldwide attention, most notably after outbreaks in United States military hospitals in Iraq and
Afghanistan. The alarming rate by which A. baumannii has attained resistance to most classes
of known antibiotics poses a great threat to our containment of the infection. A. baumannii can
rapidly modify transmembrane proteins and efflux pumps to prevent current antibiotics from
penetrating its inner membrane and executing their mechanism of action. Furthermore, the
enhanced ability of A. baumannii (Figure 2) to obtain DNA from the external environment has
allowed the species to obtain novel drug and heavy metal ion resistance genes. With
resistance documented to all known classes of antibiotics, as well as cellular mechanisms that
prevent dessication and the action of antimicrobials, the world is in great need of innovative
pharmaceuticals and antimicrobials that can eliminate this dangerous pathogen.
Genome Structure
Figure 3. The genome of Acinetobacter baumannii consists of 3,976,746 base pairs. Several
pathogenicity islands were identified in the genome through sequence homology comparisons.
Acinetobacter baumannii has several genes that permit it to pick up foreign DNA from its
environment, as well as other microbes. These genes include PilQ, ComE, and PilF,
commonly found in gram-negative bacteria, as well as closely related species Acinetobacter
baylyi. Interestingly, the genome of Acinetobacter baumannii lacks a gene for ComP, a gene
for a membrane transporter important for foreign DNA uptake in many species. Nonetheless,
the ComEA gene of A. baumannii codes for a transmembrane protein that can bind foreign
DNA in the environment and transport it to the internal environment of the cell where it can be
incorporated into the genome. One study has suggested that the ComEA gene or possibly
even the type IV pilus of A. baumannii allow it to effectively obtain foreign DNA from the
environment, thus eliminating the need for the ComP gene found in many other species (1).
Closely tied to A. baumanniii’s ability to obtain foreign DNA for incorporation into its own
genome are the putative alien islands (pAs) that permit the pathogenicity of A. baumanniii,
distinguishing it from other Acinetobacter species. pAs obtained from the environment or from
other species can possess a variety of functions. Nevertheless, many of the pAs that remain
preserved in the A. baumannii genome are responsible for pathogenic and virulence factors,
and are deemed PAIs. Of the approximately 28 pAs in the A. baumannii genome, 12 share
significant sequence identity with virulence genes in other species of bacteria. The largest of
these PAIs is a 133,740 base pair island containing several transposons, integrases, and eight
genes with significant sequence homology to Legionella/Coxiella Type IV virulence/secretion
apparatus (1). Seven of the twelve PAIs contain genes that encode proteins or efflux pumps
that confer drug resistance to A. baumanniii, although many strains of A. baumanniidevelop
additional drug resistance genes through the evolutionary pressures of treatment with
pharmaceuticals (1).
In addition to the virulence-conferring genes of the A. baumannii PAIs, the pAs obtained by
the bacterium from the outside environment include genes for heavy metal resistance, iron
metabolism, quorum sensing capabilities, lipid metabolism, amino acid uptake, and genes for
the breakdown of xenobiotics (1).
Cell Structure
Figure 4. Acinetobacter baumannii membrane transporter PilQ allows initial entry of foreign DNA into the
cell. Foreign DNA is then bound by protein ComE and is directed to cytoplasmic membrane transporter
ComA.
Unique to A. baumannii is the small amount of porins in the cell membrane. In bacterial cells,
porins allow for the transport of various molecules across the lipid membrane. Various cellular
functions and consequences have been attributed to the presence of porins in the membrane,
some helpful and others detrimental to subsistence. In some cases, porins can permit cells to
adhere to other bacterial cells (such as in the formation of biofilms). Nonetheless, porins can
allow the entry of antibiotic and other antimicrobial compounds across the cell membrane and
into the cytoplasm, where they disrupt normal enzymatic processes or destroy cellular
structures and organelles (5). The decreased porin expression observed in A. baumannii has
been viewed as another mechanism by which this pathogen sustains resistance to antibiotics
and antimicrobial agents, by simply preventing these compounds from entering the cell. For
example, A. baumannii has been able to become resistant to imipenem and carbapenem
antibiotics by eliminating several porins, including porin CarO, as well as another porin that
seems to share significant sequence homology with the OprD porin found in other gram
negative bacteria (6,7).
In addition to porins, scattered in the membrane of A. baumannii are efflux pumps that allow
for the removal of organic compounds, as well as antibiotic or antimicrobial agents that could
prove detrimental to the cell. There are several classes of efflux pumps, however, the majority
of drug efflux pumps found in A. baumannii belong to either the Major Facilitator Superfamily
(MFS) or the Resistance-Nodulation-Division (RND) family. These efflux pumps operate by
proton motive force expulsion (5).
Also found in the cell membrane of A. baumannii are protein channels and transporters
involved in the uptake of foreign DNA (Figure 4). Located in the outer membrane is PilQ,
which allows initial entry of foreign DNA. The DNA is then bound by ComE, and is transported
through the periplasmic space by PilE, or the type IV pilus to the ComA transmembrane
protein located in the inner membrane. Transport through ComA allows the DNA to enter the
cytoplasm of A. baumannii. Once inside the cell, this foreign DNA is either degraded,
integrated into the genome, or exists as a plasmid (1).
Of particular interest with regard to the cellular structure of A. baumannii is the bacteria’s outer
membrane protein A (OmpA). OmpA has been associated with the ability of A. baumannii to
form biofilms on both biological surfaces such as the human skin, as well as abiotic
environments such as catheters and shunts (8). Furthermore, OmpA is believed to be a major
component of the mechanism by which A. baumannii invades epithelial cells. OmpA allows A.
baumannii to adhere and invade epithelial cells by a zipper-like mechanism that involves the
motion of both microtubules and microfilaments (9).
Metabolism
A. baumannii are aerobic, non-fermentative, catalase-positive and oxidase-negative bacteria
(10). Like other A. baumannii species, they are unable to reduce nitrate to nitrite. They obtain
nitrogen from ammonium and nitrate salts. They are able to use various organic compounds
for metabolism and energy production, including sugars, fatty acids, some amino acids,
unbranched hydrocarbon chains, and some aromatic compounds (including aromatic amino
acids). The use of sugars as a carbon source for metabolic pathways by A. baumannii is
restricted to D-glucose, D-ribose, D-xylose, and L-arabinose (4).
A. baumannii can degrade aromatic compounds through the β-ketoadipate pathway, involving
β-ketoadipate enol-lactone hydrolase and β-ketoadipate succinyl -CoA transferase as the
primary metabolizing enzymes. Through this pathway, aromatic compounds are ultimately
converted to succinic acid and acetyl-CoA (4).
A. baumannii uses the cytochrome system in its electron transport pathways, demonstrated by
complete inhibition of NADH oxidase activity when the cells were treated with cyanide.
Cytochrome a1, cytochrome a2, cytochrome b1, cytochrome c, as well as flavin have been
shown to play a role in the electron transport pathways and cellular respiration of A.
baumannii (4).
In nucleic acid metabolism, A. baumannii must use uracil as pyrimidine in both RNA and DNA
synthesis. Because A. baumannii lacks the thymine phosphorylase and thymidine kinase
enzymes, it cannot incorporate thymine into DNA molecules (4).
Epidemiology
Figure 5. Several regions around the world are attempting to deal with outbreaks of Acinetobacter
baumannii infection. Although Acinetobacter baumannii has been a problem in hospitals for many years,
the pathogen started to receive attention after the rise in infections among soldiers serving in Iraq and
Afghanistan.
Few studies have been performed on the mortality rates associated with A.
baumannii infection. One study performed in a hospital intensive care unit suggested that A.
baumannii infection resulted in a 7.8% increase in mortality among these patients. However,
the statistical relevance of these findings has been challenged (11, 18). In a separate study, A.
baumannii infection was shown to have no relevant effect on patient mortality rate.
However, A. baumannii infection was shown to prolong a patient’s hospital stay by 4.5 days
(19).
A. baumannii infection has been an epidemiological concern in hospitals for many years.
Additionally, A. baumannii was the bacterium most isolated from open wounds during the
Vietnam War. However, it wasn’t until the outbreaks of A. baumannii infection among soldiers
serving in Iraq and Afghanistan that the pathogen garnered public attention. Between January
2002 and August 2004, A. baumannii was isolated from the blood of 102 soldiers being
treated in military health care facilities. All of the soldiers had served in either the Afghanistan
or Iraq regions, and it is believed that the majority of the cases were obtained through infection
of open wounds (11).
Pathology
Figure 6. Acinetobacter baumannii can be found in the natural microbial flora of the human skin.
However, some pathogenic strains can infect the human respiratory tract, open wounds, or the
bloodstream. Acinetobacter baumannii's resistance to many antibiotics and diverse metabolism allows it
to subsist in various environments.
Although the exact molecular mechanism by which A. baumannii gains entry into host cells
has yet to be elucidated, many theories suggest the use of outer membrane proteins. As
stated previously, it is believed that OmpA, the most abundant cell membrane protein of A.
baumannii, allows the bacteria enter epithelial cells by means of a zipper-like mechanism ( a
form of receptor-mediated entry). In this mechanism, OmpA interacts with host cell membrane
receptors. After OmpA binds to the receptor, the A. baumannii cell is surrounded and enclosed
by the host cell membrane by means of cytoskeletal rearrangement involving the
rearrangement of actin and components of the cellular membrane (9). Outer membrane
protein 38 (Omp38) has also been suggested as another protein involved in the pathogenesis
of A. baumannii. In a recent study, Omp38 was purified from A. baumannii and localized to the
mitochondrial membrane of host epithelial cells. Omp38 also induced apoptosis of epithelial
cells as a result mitochondrial disintegration upon Omp38 localization with the mitochondrial
membrane. The results observed with purified Omp38 were replicated when the cells were
infected with standard A. baumannii cells. This study promotes the idea that Omp38
contributes to the pathogenesis of A. baumannii by disintegrating the mitochondrial
membrane, causing the release of pro-apoptotic molecules, eventually leading to host cell
death (20).
A. baumannii can infect all organs, however infections are most often found in organs that
have high fluid content, such as the lungs and associated respiratory structures, the bladder
and other urinary tract structures, and the peritoneal fluid of the abdominal cavity (Figure 6)
(11). The risk of infection increases dramatically when medical devices such as ventilators,
endotracheal intubators, and catheters are inserted into these bodily tracts (21).
The most dangerous pathological consequences of A. baumannii result when the microbe
infects the respiratory tract. Infection of the respiratory tract often results in a severe case of
pneumonia for the patient. Symptoms of these A. baumannii- induced pneumonia cases are
similar to those of other respiratory infections, including high fever or hypothermia, rigors,
change in the color of septum, chest pain, and shortness of breath (21). Mortality rate from A.
baumannii-induced pneumonia can range from 40-64% if the bacteria can be isolated from the
blood or pleural effusions during the time of illness (21). Treating these cases of pneumonia
has proven difficult for health care practitioners, as A. baumannii strains have gained
resistance to most classes of antibiotics since the 1970’s. Nonetheless, a recent study found
that imipenem antibiotics proved most effective in treating A. baumannii associated
pneumonia. However, because imipenem resistance is increasing within A. baumannii strains,
it has been found that intravenous administration of colistin is an effective alternative, although
not preferred because of the compound’s nephrotoxic effect (22).
Multidrug-Resistance
A. baumannii’s role as a dangerous emerging pathogen is most directly associated with its
ability to quickly develop resistance to antibiotic and antimicrobial compounds (Figure 7).
There are several mechanisms by which A. baumannii has been able to develop resistance to
most classes of antibiotics. By reducing porin expression, increasing expression of certain
transmembrane efflux pumps, and acquiring foreign DNA from the environment, including
plasmids with a multitude of antibiotic resistance genes, enable A. baumannii to survive even
the most aggressive pharmaceutical treatments (23, 24). Mechanisms of resistance to
selected classes of antibiotics are detailed below.
Several epidemiological studies have confirmed that most cases of A. baumannii are obtained
in hospitals or other healthcare facilities (14). Additionally, most cases are associated with
long-term hospital stays or admittance to intensive care units. Without proper sterilization
techniques, A. baumannii can colonize medical equipment and supplies. The identification
of A. baumannii as an inhabitant of the skin flora suggests the possibility that this pathogen
can be transmitted to patients from physical contact with their healthcare providers (11). The
conditions that would warrant patient hospitalization are closely associated with immune
impairment. The high concentrations of immune compromised patients, coupled with ideal
growing surfaces (catheters, shunts, ventilators), and the physical contact required for
adequate care make hospitals ideal environments for the spread of A. baumannii. The
resistance of this microbe to most classes of antibiotics has made outbreaks of A.
baumannii within hospitals even more frightening for patients and healthcare providers alike.
References
1Smith, M.G.; Gianoulis, T.A.; Pukatzski, S.; Mekalanos, J.J.; ornston, L.N.; Gerstein, M.;
Snyder, M. 2007. New insights into Acinetobacter baumannii pathogenesis revealed by high-
density pyrosequencing and transposon mutagenesis Genes & Dev. 2007. 21: 601-614
2Fournier P.E.; Vallenet, D.; Barbe, V.; Audic, S.; Ogata, H. 2006 Comparative Genomics of
Multidrug Resistance in Acinetobacter baumannii. PLoS Genet 2(1): e7.
doi:10.1371/journal.pgen.0020007
3 Iacono, M.; Villa, L.; Fortini, D.; Bordoni, R.; Imperi, F.; Bonnal, R.J.P.; Sicheritz-Ponten, J.;
DeBellis, G.; Visca, P.; Cassone, A.; Carattoli, A. 2008. Whole-Genome Pyrosequencing of an
Epidemic Multidrug-Resistant Acinetobacter baumannii Strain Belonging to the European
Clone II Group. Antimicrobial Agents and Chemotherapy 52(7): 2616–2625.
4 Juni, E. 1978. Genetics and Physiology of Acinetobacter. Ann. Rev. Microbiol. 32:349-371.
5 Vila, J.; Marti, S.; Sanchez-Cespedes, J. 2007.Porins, efflux pumps and multidrug resistance
in Acinetobacter baumannii. 59(6):1210-1215.
6 del Mar Tomas, M.; Beceiro, A.; Perez, A.; Velasco, D.; Moure, R.; Villanueva, R.; Martinez-
Beltran, J.; Bou, G. 2005. Cloning and Functional Analysis of the Gene Encoding the 33- to
36-Kilodalton Outer Membrane Protein Associated with Carbapenem Resistance in
Acinetobacter baumannii. 49(12):5172-5175.
7 Mussi, M.A.; Limansky, A.S.; Viale, A.M. 2005. Acquisition of resistance to carbapenems in
multidrug-resistant clinical strains of Acinetobacter baumannii: natural insertional inactivation
of a gene encoding a member of a novel family of β-barrel outer membrane proteins.
Antimicrob Agents Chemother. 49:1432-40.
8 Gaddy, J.A.; Tomaras, A.P.; Actis, L.A. 2009. The Acinetobacter baumannii 19606 OmpA
Protein Plays a Role in Biofilm Formation on Abiotic Surfaces and in the Interaction of This
Pathogen with Eukaryotic Cells. Infect Immun.77(8): 3150–3160.
9 Choi, C.H.; Lee, J.S.; Lee, Y.C.; Park, T.I.; Lee, J.C. 2008. Acinetobacter baumannii invades
epithelial cells and outer membrane protein A mediates interactions with epithelial cells. BMC
Microbiology 8(216):1-11.
10 Van Looveren, M.; Goossens, H.; ARPAC Steering Group. 2004. Antimicrobial resistance
of Acinetobacter spp. in Europe. Clinical Microbiology and Infection 10(8): Article first
published online: 9 AUG 2004
11 Fournier, P.E.; Richet, H. 2006. The Epidemiology and Control of Acinetobacter baumannii
in Health Care Facilities. Health Care Epidemiology 42(1):692-699.
12 Miller, L.A.; Mera, R.; Amrine-Madsen, H.; Sahm, D.F. 2009. Marked increase of
Acinetobacter baumannii resistance to multiple antibiotics during the period 2002-2007 in a
large US surveillance study. Biometrics. September 2009:C2-622.
13 Apisarnthanarak, A.; Pinitchai, U.; Thongphubeth, K.; Yuekyen,C.; Warren, D.K.; Fraser,
V.J. 2008. A Multifaceted Intervention to Reduce Pandrug-Resistant Acinetobacter baumannii
Colonization and Infection in 3 Intensive Care Units in a Thai Tertiary Care Center: A 3-Year
Study. Clin Infect Dis.47(6):760-767.
14 Rodriguez-Bano, J.; Cisneros, J.M.; Fernandez-Cuenca ,F. 2004. Clinical features and
epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals.
Infect Control Hosp Epidemiol 25:819–824.
15 Corbella ,X.; Pujol, M.; Ayats, J. 1996. Relevance of digestive tract colonization in the
epidemiology of nosocomial infections due to multiresistant A. baumannii. Clin Infect Dis 1996;
23:329–334.
16 La Scola, B.; Raoult, D. 2004. Acinetobacter baumannii in human body louse. Emerg Infect
Dis 10:1671–1673.
17 Mc Donald, C.L.; Banerjee, S.N.; Jarvis W.R. 1999. Seasonal variation in Acinetobacter
infection: 1987–1996. Clin Infect Dis 29:1133–1137.
19 Daniels, T.L.; Deppen, S.; Arbogast, P.G.; Griffin, M.R.; Schaffner, W.; Talbot, T.R. 2008.
Mortality rates associated with multidrug-resistant Acinetobacter baumannii infection in
surgical intensive care units. Infect Control Hosp Epidemiol.29(11):1080-1083.
20 Choi, C.H.; Lee, E.Y.; Lee, Y.C.; Park, T.I.; Kim, H.J.; Hyun, S.H.; Kim, S.A., Lee, S.K.,
Lee, J.C. 2005. Outer membrane protein 38 of Acinetobacter baumannii localizes to the
mitochondria and induces apoptosis of epithelial cells. Cell Microbiol.7(8):1127-1138.
21 Chen, M.Z.; Hsueh, P.R.; Lee, L.N.; Yu,C.J.; Yang, P.C.; Luh, K.T. 2001. Severe
community-acquired pneumonia due to Acinetobacter baumannii. Chest. 120(4):1072-1077.
23 Fernández-Cuenca, F.; Martínez-Martínez, L.; Conejo, M.C.; Ayala, J.A.; Perea, E.J.;
Pascual, A. 2003. Relationship between beta-lactamase production, outer membrane protein
and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of
Acinetobacter baumannii. J Antimicrob Chemother. 51(3):565-574
24Poole, K. 2005. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother.
56(1):20-51.
25 Huys, G.; Cnockaert, M.; Vaneechoutte, M.; Woodford, N.; Nemec, A.; Dijkshoorn, L.;
Swings, J. 2005. Distribution of tetracycline resistance genes in genotypically related and
unrelated multiresistant Acinetobacter baumannii strains from different European
hospitals.Res Microbiol. 156(3):348-355
26 Ribera, A.; Ruiz, J.; Vila, J. 2003. Presence of the Tet M determinant in a clinical isolate of
Acinetobacter baumannii. Antimicrob Agents Chemother.47(7):2310-2312.
27 Gales, A.C.; Reis, A.O.; Jones, R.N. 2001. Contemporary assessment of antimicrobial
susceptibility testing methods for polymyxin B and colistin: review of available interpretative
criteria and quality control guidelines. J Clin Microbiol. 39(1):183-190.
28 Reis, A.O.; Luz, D.A.; Tognim, M.C.; Sader, H.S.; Gales, A.C. 2003. Polymyxin-resistant
Acinetobacter spp. isolates: what is next? Emerg Infect Dis.9(8):1025-1027.
29 Peterson, A.A.; Fesik, S.W.; McGroarty, E.J. 1987. Decreased binding of antibiotics to
lipopolysaccharides from polymyxin-resistant strains of Escherichia coli and Salmonella
typhimurium. Antimicrob Agents Chemother. 31(2):230-237.
30 Vila, J.; Ruiz, J.; Goñi, P.; Jimenez de Anta, T. 1997. Quinolone-resistance mutations in the
topoisomerase IV parC gene of Acinetobacter baumannii. J Antimicrob Chemother. 39(6):757-
762.
31 Scerpella, E.G.; Wanger, A.R.; Armitige, L.; Anderlini, P.; Ericsson, C.D. 1995. Nosocomial
outbreak caused by a multiresistant clone of Acinetobacter baumannii: results of the case-
control and molecular epidemiologic investigations. Infect Control Hosp Epidemiol. 16(2):92-7.
32 Chopra, S.; Torres-Ortiz, M.; Hokama, L.; Madrid, P.; Tanga, M.; Mortelmans, K.;
Kodukula, K.; Galande, A.K. 2010. Repurposing FDA-approved drugs to combat drug-
resistant Acinetobacter baumannii. J Antimicrob Chemother.65(12):2598-2601
Edited by Kerri-Lynn Conrad, student of Joan Slonczewski for BIOL 238 Microbiology,
2011, Kenyon College.
Categories:
Curated Pages
page
discussion
view source
history
Log in
navigation
MicrobeWiki Home
Study Microbes
Microbial Biorealm
Viral Biorealm
Microbial Mythology
Recent changes
Random page
Contact MicrobeWiki
Help
search
Go Search
tools
Related changes
Special pages
Printable version
Permanent link
This page was last modified on 12 May 2011, at 17:53.
Privacy policy
About MicrobeWiki
Disclaimers